Participated · Equity · Jan 2025

Robeauté is developing a therapeutic microrobotic platform built around a universal robotic carrier with interchangeable micro-extensions that can deliver drugs, implant electrodes, collect tissue samples or capture real-time data from deep in the brain. The active robots, continuously tracked by ultrasound, move along curved, non-linear paths inside brain tissue, providing surgeons with unprecedented control compared with magnetically driven probes. The company holds more than 50 patents and positions its platform to address large markets such as brain cancer, biopsies, targeted drug delivery and brain–computer interfaces. Founded in 2017 by robotics veteran Bertrand Duplat and operations specialist Joana Cartocci, Robeauté operates from Paris and recently opened a U.S. subsidiary to facilitate clinical trials and commercialization. Its first-in-human studies are targeted for completion by the end of 2026, with the U.S. expected to be the initial launch market due to a more collaborative regulatory environment. In January 2025 the company secured $28 million in new funding, enabling it to double its team and accelerate product development. While revenue and user numbers have not been disclosed, the fresh capital provides runway for expanded hiring across scientific, engineering, quality, regulatory and go-to-market roles.

Led · Series E · Sep 2024

Inflammatix is reimagining infectious-disease diagnostics by using proprietary host-response biomarkers and machine learning to measure gene expression patterns from a finger-stick blood sample. Its sample-to-answer Myrna instrument platform delivers results in under 30 minutes and is being paired with the ViraBac EZ test, which tells physicians whether an infection is bacterial or viral so they can prescribe antibiotics appropriately. The company’s initial focus areas are acute infections and sepsis, large markets where faster, more precise information can improve outcomes and curb antibiotic resistance. Inflammatix’s technology aims to reduce the estimated 30 % of antibiotics that are inappropriately prescribed in U.S. outpatient settings each year. Commercialization efforts are currently supported by non-dilutive government funding and venture backing from Khosla Ventures, Northpond Ventures, Stanford StartX Fund, Think.Health Ventures, and OSF Ventures. A BARDA contract worth up to $72 million, if all options are exercised, underpins ongoing product development. The latest tranche of BARDA financing brings additional resources to finalize the testing system and move it toward market launch.

Led · Series C · Aug 2024

SphingoTec focuses on developing and marketing novel blood-based biomarkers such as Proenkephalin A 119-159 (penKid) and bioactive Adrenomedullin 1-52 (bio-ADM). These biomarkers aim to improve assessment of kidney and endothelial function and support management of critically ill patients. The company plans to out-license and commercialize its assays to translate scientific advances into routine clinical practice. Management intends to collaborate with key diagnostic-industry players to expand market reach, including targeted efforts to penetrate the US market. Think.Health Ventures’ diagnostics expertise and network are expected to add strategic value to those commercialization efforts. The company recently completed a financing to support global expansion and continued market development. sphingotec, founded in 2002 and based in Hennigsdorf, Germany, develops and markets biomarker diagnostics including penKid® and bio‑ADM® for prediction, diagnosis and therapy monitoring of AKI, congestive heart failure and septic shock. The company also owns the Nexus IB10 point-of-care (POC) immunoassay platform acquired from Nexus Dx Inc. in May 2018 and plans to roll out the fully automated IB 10 POC platform. More than 1,000 intensive care units, emergency departments, smaller hospitals and larger practices in Europe and the Middle East use its platform regularly, with over 100,000 tests performed per year. sphingotec is developing a pipeline of novel biomarkers intended to predict risks of obesity, breast cancer and cardiovascular diseases. The company intends to use the new financing to support commercial expansion and the IB 10 POC platform rollout.

Participated · Series A · Jan 2024

Myosotis offers a software-as-a-service solution for direct digital communication between employees, relatives, and third-party service providers in care homes. The app supports photos, videos, voice messages and video calls, consolidating most communication and administrative processes into a single digital application. Led by CEO Jasper Böckel, myo enables homes to inform relatives about hygiene measures, let families participate in residents' lives, and notify doctors, pharmacies or external laundry services. The company works with over 400 customers in DACH and the UK, including DRK, AWO, Johanniter and Agaplesion. Myosotis raised €8M in Series A funding and intends to use the proceeds to grow in the DACH region and the UK, expand marketing capacity, enhance service quality, and develop new modules. The financing will support continued roll-out of their technology to more users and additional solutions for healthcare providers and families.

Participated · Equity · Feb 2023

Selfapy provides online courses grounded in cognitive behavioral therapy to reduce symptoms of depression and generalized anxiety disorder. The company recently added two new courses for binge-eating disorder and bulimia nervosa, becoming the first reimbursed DiGA provider for eating disorders in Germany. Led by Co-CEOs Nora Blum and Adham Kassab, Selfapy focuses on expanding its digital therapeutics portfolio. The company plans to use new funding to develop additional digital therapeutics, grow its presence in the German market, and enter other European markets. Selfapy is based in Berlin and delivers reimbursable digital health offerings within the German healthcare system. The company closed a €7m financing round to support these initiatives. Selfapy offers online therapy courses based on cognitive behavioural therapy for conditions including depression, anxiety and eating disorders. Courses can be completed anonymously and flexibly, under the supervision of psychologists. The platform already cooperates with 16 health insurance companies in Germany and Switzerland and has treated more than 15,000 patients. Selfapy plans to use the new funding for national and international expansion, further product development and additional clinical validation of its online therapy platform. The company was founded in February 2016 and is based in Berlin, Germany. Selfapy operates an online platform of therapy courses designed to help people with mental illness. The courses are supplemented by support from a psychologist via telephone or chat and are not intended to fully replace traditional therapy. The company is based in Berlin. With the new capital it plans to expand B2B sales, develop its app, and deepen cooperation with health insurance companies. Since April some courses have been reimbursable by insurers and others are expected to follow. Selfapy recently raised a seven-digit investment estimated between €1 million and €2 million from IBB Beteiligungsgesellschaft and High‑Tech Gründerfonds.